{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(23)"],"submitter":["Bonechi M"],"pubmed_abstract":["The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression. CTCs count and <i>ESR1</i>/<i>PIK3CA</i> mutations in circulating tumor DNA were performed and correlated with TK1 activity. TK1 activity was reduced in the two endocrine-sensitive cell lines after 2 days of treatment. In patients"],"journal":["Oncotarget"],"pagination":["16389-16399"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5893248"],"repository":["biostudies-literature"],"pubmed_title":["Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy."],"pmcid":["PMC5893248"],"pubmed_authors":["Biagioni C","Bergqvist M","Pestrin M","Galardi F","Gabellini S","Di Leo A","Malorni L","Boccalini G","Neumuller M","Guarducci C","De Luca F","Migliaccio I","Bonechi M"],"additional_accession":[]},"is_claimable":false,"name":"Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.","description":"The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression. CTCs count and <i>ESR1</i>/<i>PIK3CA</i> mutations in circulating tumor DNA were performed and correlated with TK1 activity. TK1 activity was reduced in the two endocrine-sensitive cell lines after 2 days of treatment. In patients","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2025-04-18T13:08:54.383Z","creation":"2019-03-26T23:29:27Z"},"accession":"S-EPMC5893248","cross_references":{"pubmed":["29662653"],"doi":["10.18632/oncotarget.24700"]}}